In a recent comparative study between nivolumab-sensitive and nivolumab-resistant NSCLC patients, the latter exhibited a high infiltration of M2-type TAMs and a lower density of CD8+ T and NK cell infiltration in primary tumor tissue [530]. The gene discussed is CD8A; the disease is neoplasm.